Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

作者：Xiaofeng Li, Yueming He, Jinfeng Zhu, Hongxia Pang, Yongwei Lin, Jinyang Zheng · 发表于：Oncotarget · 年份：2018 · DOI：10.18632/oncotarget.25989 · 被引用次数：15 · 研究领域：Metastasis and carcinoma case studies、Cancer Diagnosis and Treatment、Gastrointestinal Tumor Research and Treatment

// Xiaofeng Li 1 , Yueming He 2 , Jinfeng Zhu 1 , Hongxia Pang 1 , Yongwei Lin 1 and Jinyang Zheng 3 1 Department of Oncology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China 2 Department of Respiratory Diseases, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China 3 Department of Pathology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China Correspondence to: Jinyang Zheng, email: Listar@tom.com Keywords: angiogenesis; apatinib; sarcomatoid carcinoma; targeted therapy Received: September 29, 2017      Accepted: March 17, 2018      Published: September 14, 2018 ABSTRACT Sarcomatoid carcinoma is a rare malignancy characterized by a combination of epithelial and sarcoma or sarcoma-like components. In this study, we reported one case of pulmonary sarcomatoid carcinoma and evaluated the safety and efficacy of apatinib, a tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptor 2, in treating this disease. The tumor mass was detected in the left lung of a 75-year-old man and showed positive immunostaining for cytokeratin (CK) 7, CK8, smooth muscle actin, CD31, and CD34. Next-generation sequencing analysis identified 4 mutations in NF1 (p.Q347Sfs * 29), CDKN2A (p.G23V), ERBB3 (p.V104L), and TP53 (p.V157F) genes. The patient was given apatinib (250 mg) orally once per day. Sustained tumor ...